Spruce Biosciences, Inc. Gain (Loss) on Termination of Lease
Spruce Biosciences, Inc. (SPRB) reported Gain (Loss) on Termination of Lease of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-18.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnTerminationOfLease · last filed 2024-03-18
- Spruce Biosciences, Inc. gain (loss) on termination of lease for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Spruce Biosciences, Inc. gain (loss) on termination of lease for fiscal 2022 was $750.00K.
- Spruce Biosciences, Inc. gain (loss) on termination of lease for fiscal 2021 was $0.00.
| Period end | Gain (Loss) on Termination of Lease 12 month |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-18 |
| 2022-12-31 | $750.00K 10-K · filed 2024-03-18 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |